Trial Profile
Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Azathioprine; Methotrexate; Mycophenolate
- Indications Conjunctivitis; Pemphigoid
- Focus Therapeutic Use
- 12 Sep 2023 Status changed from recruiting to discontinued.
- 21 Apr 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 09 Mar 2022 New trial record